Synthetic molecular sensors based on CRISPR-Cas9 redirect anticancer signal flows to treat retinoblastomas.
Clinical and translational medicine, 11(11): e618 PMID 34841725 DOI 10.1002/ctm2.618
Abstract
This article has no abstract in PubMed.
Your browser does not allow saving data (e.g. private mode): bookmarks will be lost when the tab closes.